Diagnosis and management of Wilson's disease: Results of a single center experience

Valentina Medici, Carlo Pietro Trevisan, Renata D'Incà, Michela Barollo, Lucia Zancan, Stefano Fagiuoli, Diego Martines, Paola Irato, Giacomo Carlo Sturniolo

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

AIMS: To report on the diagnostic features, management, and clinical outcome after different treatments of Wilson's disease patients followed over a mean period of 15 years. PATIENTS: Thirty-five patients with Wilson's disease referred to the University of Padova's Department of Gastroenterology for diagnosis or treatment were observed for a mean 15 years. The diagnosis was based on clinical symptoms, laboratory tests (ceruloplasmin, urinary, and hepatic copper concentrations), and uptake of the radiostable isotope Cu into the plasma protein pool. Hepatic Cu content was measured by regular follow-up biopsies. Neurologic outcome after therapy was assessed using a newly developed scoring system. RESULTS: Twenty-three (65.7%) patients presented with liver disease; 12 (34.3%) had mixed neurologic and hepatic involvement. All patients had been initially treated with either penicillamine (23) or zinc sulfate (12). The neurologic symptoms became worse or remained stationary in 75% of those treated with penicillamine, whereas zinc treatment improved these symptoms in 90% of treated cases. Both treatments were effective in improving the hepatic symptoms. No differences in hepatic Cu content emerged between follow-up biopsies in either treatment group. Six patients (26%) had to abandon the penicillamine treatment due to side effects. In all, 4 patients underwent liver transplantation, which was successful in 3, with a mean survival after transplantation of 4.6 years; the fourth, who had a severe neurologic impairment, died of central pontine myelinolysis. CONCLUSIONS: Penicillamine and zinc can effectively treat Wilson's disease, though the side effects of penicillamine may be severe enough to prompt its suspension. Liver transplantation remains the treatment of choice for end-stage liver disease.

Original languageEnglish (US)
Pages (from-to)936-941
Number of pages6
JournalJournal of Clinical Gastroenterology
Volume40
Issue number10
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Hepatolenticular Degeneration
Penicillamine
Liver
Nervous System
Therapeutics
Liver Transplantation
Zinc
Central Pontine Myelinolysis
Zinc Sulfate
Biopsy
End Stage Liver Disease
Ceruloplasmin
Gastroenterology
Neurologic Manifestations
Isotopes
Liver Diseases
Blood Proteins
Copper
Suspensions
Transplantation

Keywords

  • Diagnosis
  • Follow up
  • Therapy
  • Wilson's disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Medici, V., Trevisan, C. P., D'Incà, R., Barollo, M., Zancan, L., Fagiuoli, S., ... Sturniolo, G. C. (2006). Diagnosis and management of Wilson's disease: Results of a single center experience. Journal of Clinical Gastroenterology, 40(10), 936-941. https://doi.org/10.1097/01.mcg.0000225670.91722.59

Diagnosis and management of Wilson's disease : Results of a single center experience. / Medici, Valentina; Trevisan, Carlo Pietro; D'Incà, Renata; Barollo, Michela; Zancan, Lucia; Fagiuoli, Stefano; Martines, Diego; Irato, Paola; Sturniolo, Giacomo Carlo.

In: Journal of Clinical Gastroenterology, Vol. 40, No. 10, 11.2006, p. 936-941.

Research output: Contribution to journalArticle

Medici, V, Trevisan, CP, D'Incà, R, Barollo, M, Zancan, L, Fagiuoli, S, Martines, D, Irato, P & Sturniolo, GC 2006, 'Diagnosis and management of Wilson's disease: Results of a single center experience', Journal of Clinical Gastroenterology, vol. 40, no. 10, pp. 936-941. https://doi.org/10.1097/01.mcg.0000225670.91722.59
Medici, Valentina ; Trevisan, Carlo Pietro ; D'Incà, Renata ; Barollo, Michela ; Zancan, Lucia ; Fagiuoli, Stefano ; Martines, Diego ; Irato, Paola ; Sturniolo, Giacomo Carlo. / Diagnosis and management of Wilson's disease : Results of a single center experience. In: Journal of Clinical Gastroenterology. 2006 ; Vol. 40, No. 10. pp. 936-941.
@article{603bf950bcf44dc496453947bcae0d04,
title = "Diagnosis and management of Wilson's disease: Results of a single center experience",
abstract = "AIMS: To report on the diagnostic features, management, and clinical outcome after different treatments of Wilson's disease patients followed over a mean period of 15 years. PATIENTS: Thirty-five patients with Wilson's disease referred to the University of Padova's Department of Gastroenterology for diagnosis or treatment were observed for a mean 15 years. The diagnosis was based on clinical symptoms, laboratory tests (ceruloplasmin, urinary, and hepatic copper concentrations), and uptake of the radiostable isotope Cu into the plasma protein pool. Hepatic Cu content was measured by regular follow-up biopsies. Neurologic outcome after therapy was assessed using a newly developed scoring system. RESULTS: Twenty-three (65.7{\%}) patients presented with liver disease; 12 (34.3{\%}) had mixed neurologic and hepatic involvement. All patients had been initially treated with either penicillamine (23) or zinc sulfate (12). The neurologic symptoms became worse or remained stationary in 75{\%} of those treated with penicillamine, whereas zinc treatment improved these symptoms in 90{\%} of treated cases. Both treatments were effective in improving the hepatic symptoms. No differences in hepatic Cu content emerged between follow-up biopsies in either treatment group. Six patients (26{\%}) had to abandon the penicillamine treatment due to side effects. In all, 4 patients underwent liver transplantation, which was successful in 3, with a mean survival after transplantation of 4.6 years; the fourth, who had a severe neurologic impairment, died of central pontine myelinolysis. CONCLUSIONS: Penicillamine and zinc can effectively treat Wilson's disease, though the side effects of penicillamine may be severe enough to prompt its suspension. Liver transplantation remains the treatment of choice for end-stage liver disease.",
keywords = "Diagnosis, Follow up, Therapy, Wilson's disease",
author = "Valentina Medici and Trevisan, {Carlo Pietro} and Renata D'Inc{\`a} and Michela Barollo and Lucia Zancan and Stefano Fagiuoli and Diego Martines and Paola Irato and Sturniolo, {Giacomo Carlo}",
year = "2006",
month = "11",
doi = "10.1097/01.mcg.0000225670.91722.59",
language = "English (US)",
volume = "40",
pages = "936--941",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Diagnosis and management of Wilson's disease

T2 - Results of a single center experience

AU - Medici, Valentina

AU - Trevisan, Carlo Pietro

AU - D'Incà, Renata

AU - Barollo, Michela

AU - Zancan, Lucia

AU - Fagiuoli, Stefano

AU - Martines, Diego

AU - Irato, Paola

AU - Sturniolo, Giacomo Carlo

PY - 2006/11

Y1 - 2006/11

N2 - AIMS: To report on the diagnostic features, management, and clinical outcome after different treatments of Wilson's disease patients followed over a mean period of 15 years. PATIENTS: Thirty-five patients with Wilson's disease referred to the University of Padova's Department of Gastroenterology for diagnosis or treatment were observed for a mean 15 years. The diagnosis was based on clinical symptoms, laboratory tests (ceruloplasmin, urinary, and hepatic copper concentrations), and uptake of the radiostable isotope Cu into the plasma protein pool. Hepatic Cu content was measured by regular follow-up biopsies. Neurologic outcome after therapy was assessed using a newly developed scoring system. RESULTS: Twenty-three (65.7%) patients presented with liver disease; 12 (34.3%) had mixed neurologic and hepatic involvement. All patients had been initially treated with either penicillamine (23) or zinc sulfate (12). The neurologic symptoms became worse or remained stationary in 75% of those treated with penicillamine, whereas zinc treatment improved these symptoms in 90% of treated cases. Both treatments were effective in improving the hepatic symptoms. No differences in hepatic Cu content emerged between follow-up biopsies in either treatment group. Six patients (26%) had to abandon the penicillamine treatment due to side effects. In all, 4 patients underwent liver transplantation, which was successful in 3, with a mean survival after transplantation of 4.6 years; the fourth, who had a severe neurologic impairment, died of central pontine myelinolysis. CONCLUSIONS: Penicillamine and zinc can effectively treat Wilson's disease, though the side effects of penicillamine may be severe enough to prompt its suspension. Liver transplantation remains the treatment of choice for end-stage liver disease.

AB - AIMS: To report on the diagnostic features, management, and clinical outcome after different treatments of Wilson's disease patients followed over a mean period of 15 years. PATIENTS: Thirty-five patients with Wilson's disease referred to the University of Padova's Department of Gastroenterology for diagnosis or treatment were observed for a mean 15 years. The diagnosis was based on clinical symptoms, laboratory tests (ceruloplasmin, urinary, and hepatic copper concentrations), and uptake of the radiostable isotope Cu into the plasma protein pool. Hepatic Cu content was measured by regular follow-up biopsies. Neurologic outcome after therapy was assessed using a newly developed scoring system. RESULTS: Twenty-three (65.7%) patients presented with liver disease; 12 (34.3%) had mixed neurologic and hepatic involvement. All patients had been initially treated with either penicillamine (23) or zinc sulfate (12). The neurologic symptoms became worse or remained stationary in 75% of those treated with penicillamine, whereas zinc treatment improved these symptoms in 90% of treated cases. Both treatments were effective in improving the hepatic symptoms. No differences in hepatic Cu content emerged between follow-up biopsies in either treatment group. Six patients (26%) had to abandon the penicillamine treatment due to side effects. In all, 4 patients underwent liver transplantation, which was successful in 3, with a mean survival after transplantation of 4.6 years; the fourth, who had a severe neurologic impairment, died of central pontine myelinolysis. CONCLUSIONS: Penicillamine and zinc can effectively treat Wilson's disease, though the side effects of penicillamine may be severe enough to prompt its suspension. Liver transplantation remains the treatment of choice for end-stage liver disease.

KW - Diagnosis

KW - Follow up

KW - Therapy

KW - Wilson's disease

UR - http://www.scopus.com/inward/record.url?scp=33750605241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750605241&partnerID=8YFLogxK

U2 - 10.1097/01.mcg.0000225670.91722.59

DO - 10.1097/01.mcg.0000225670.91722.59

M3 - Article

C2 - 17063115

AN - SCOPUS:33750605241

VL - 40

SP - 936

EP - 941

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 10

ER -